z-logo
Premium
Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients
Author(s) -
De Keyser Myrjam,
De Belder Maya,
De Belder Jonas,
De Groot Veva
Publication year - 2018
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.13509
Subject(s) - medicine , glaucoma , intraocular pressure , randomized controlled trial , ophthalmology , medical therapy , glaucoma medication , surgery
Purpose We examined selective laser trabeculoplasty ( SLT ) as a replacement therapy for medically controlled open‐angle glaucoma (OAG) or ocular hypertensive patients. Methods A prospective randomized interventional clinical trial on 143 glaucoma patients. Patients were randomized to either receiving SLT or to the control group that continued on pressure lowering medication. Data were recorded 1 hr, 1 week, 1, 3, 6, 12 and 18 months after SLT . Primary outcome was number of medications at 12 and 18 months while maintaining a predetermined target intraocular pressure ( IOP ). Results Selective laser trabeculoplasty (SLT) reduced number of medications from a mean of 1.5 at baseline, to 0.35 after 12 months and 0.29 after 18 months. Meanwhile, SLT achieved more than 20% IOP lowering in 95% of eyes and more than 30% IOP lowering in 86% of eyes after 18 months. Seventy‐seven per cent of our eyes no longer needed any medication after SLT at 18 months. Conclusion Selective laser trabeculoplasty (SLT) enabled a reduction in number of medications while maintaining good IOP control. Selective laser trabeculoplasty (SLT) was able to completely replace medical therapy in 77% of eyes after 18 months. Selective laser trabeculoplasty (SLT) as replacement therapy may reduce local and systemic side‐effects and prevent adherence issues.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here